Allo-Hematopoietic Stem Cell Transplant Clinical Trials

A listing of Allo-Hematopoietic Stem Cell Transplant medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 94 clinical trials
Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT

In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with lymphoid malignancies.

  • 0 views
  • 04 Jun, 2021
  • 1 location
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

This is an open-label, single institution, phase II study in patients with epidermolysis bullosa (EB). The underlying hypothesis is that the infusion of bone marrow or umbilical cord blood from a healthy unaffected donor will correct the collagen, laminin, integrin, or plakin deficiency and reduce the skin fragility characteristic of …

mutation analysis
deficiency
mycophenolate mofetil
cyclophosphamide
allogeneic hematopoietic stem cell transplant
  • 37 views
  • 30 May, 2021
  • 1 location
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or haploidentical) or matched unrelated donor for the biochemical correction of severe epidermolysis bullosa (EB).

mutation analysis
deficiency
cyclophosphamide
thymoglobulin
ejection fraction
  • 169 views
  • 03 Jun, 2021
  • 1 location
Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT

Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with graft failure (GF) after allogeneic bone marrow (BM) transplantation. Since only few MSCs reach the BM after intravenous injection, …

  • 0 views
  • 22 Jan, 2021
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

The investigators hypothesize that MGD006 for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting

  • 0 views
  • 31 May, 2021
  • 1 location
Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment of malignant hematopoietic diseases. However, poor hematopoietic reconstitution including poor graft

remission
acute leukemia
n-acetylcysteine
cell transplantation
  • 0 views
  • 26 Jan, 2021
  • 1 location
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

disease whose life expectancy is significantly reduced. As a result, reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (allo-HCT) has been investigated as a

lymphoid leukemia
hematologic malignancy
richter syndrome
rituximab
chronic lymphocytic leukemia
  • 12 views
  • 08 Nov, 2020
  • 2 locations
Study to Investigate the Pharmacokinetics Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

, receiving allo-HSCT who are at high risk of GF as defined in the inclusion criteria will be included in the study. The main objective of the study is to determine the appropriate emapalumab dose regimen

  • 0 views
  • 15 May, 2021
  • 5 locations
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

(allo-HCT). However, the complete remission (CR) rates and long term survival remain very poor in these patients and, therefore, there is an unmet need to develop more effective treatment approaches in

  • 24 views
  • 15 Apr, 2021
  • 1 location
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for many malignant or nonmalignant hematological diseases. Hemorrhagic cystitis (HC) is one of

hemorrhagic cystitis
acute graft-versus-host disease
tissue damage
clot formation
graft versus host disease
  • 0 views
  • 24 Jan, 2021
  • 1 location